Research programme: CCNA2 gene therapy - VentriNova

Alternative Names: Cyclin A2 gene therapy - VentriNova; VN-100; VN-200

Latest Information Update: 26 Feb 2014

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator VentriNova
Class Gene therapies
Mechanism of Action Cyclin-dependent kinase modulators; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Preclinical Myocardial infarction

Most Recent Events

25 Feb 2014 VentriNova is open to partnering opportunities for development of this research programme. www.ventrinovainc.com
19 Feb 2014 Preclinical trials in Myocardial infarction in USA (unspecified route)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.